F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comCupid Ltd is one of India’s leading manufacturers of male and female condoms, diagnostic kits, and personal healthcare products. The company has built a strong presence in both domestic and international markets, supplying to government bodies, NGOs, and global health organizations. Over the years, Cupid Ltd has benefited from rising awareness around sexual health, population control initiatives, and increasing healthcare spending across emerging markets.
With consistent business expansion, export growth, and a niche product portfolio, Cupid Ltd has attracted significant investor interest. In this article, we analyze Cupid Ltd share price targets from 2026 to 2030 based on current market data, business fundamentals, industry trends, and long-term growth prospects.
Open: ₹472.00
Previous Close: ₹469.00
Day’s High: ₹474.80
Day’s Low: ₹461.05
VWAP: ₹470.62
52-Week High: ₹475.00
52-Week Low: ₹55.75
All-Time High: ₹475.00
All-Time Low: ₹5.20
Market Capitalization: ₹12,677 Cr
Volume: 49,17,691
Value (Lacs): 23,231.17
20D Avg Volume: 38,86,401
20D Avg Delivery (%): 27.56%
Face Value: ₹1
Book Value Per Share: ₹14.21
Beta: 0.76
UC Limit: ₹562.80
LC Limit: ₹375.20
Cupid Ltd operates in the healthcare and personal wellness segment, focusing primarily on contraceptives and allied medical products. Its product portfolio includes:
Male and female condoms
Lubricants and contraceptive devices
Diagnostic and healthcare-related products
The company has established a strong export-oriented business model, with supplies to international agencies and government tenders forming a major revenue base.
Strong presence in global contraceptive markets
Leadership position in female condom manufacturing
Consistent demand from government and NGO contracts
Export-focused revenue providing geographic diversification
Relatively low beta indicating stable stock behavior
Cupid Ltd has shown strong revenue and profit growth over recent years, supported by rising global demand for reproductive health products. Improved operating efficiencies and economies of scale have supported margin expansion. The company’s relatively small market size allows room for faster growth compared to large-cap peers.
Retail & Others: 51.52%
Promoters: 45.55%
Foreign Institutions: 2.58%
Other Domestic Institutions: 0.18%
Mutual Funds: 0.16%
High promoter holding reflects management confidence in the company’s long-term strategy, while steady retail participation highlights growing market interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 520 | 580 |
| 2027 | 600 | 670 |
| 2028 | 680 | 760 |
| 2029 | 770 | 860 |
| 2030 | 880 | 1,000 |
These projections consider export growth, healthcare demand, margin stability, and long-term sector tailwinds.
By 2026, Cupid Ltd may benefit from stable government orders and expanding international reach.
Growth Drivers
Consistent demand for contraceptive products
Expansion in export markets
Rising healthcare awareness
Investment View
Suitable for medium-term investors seeking steady growth with lower volatility.
2027 could see improved profitability as operating leverage strengthens.
Growth Drivers
Better capacity utilization
Improved margins through cost optimization
Increased repeat international orders
Investment View
Positive outlook for investors looking for defensive healthcare exposure.
By 2028, Cupid Ltd may demonstrate more predictable earnings growth.
Growth Drivers
Scaling of core contraceptive business
Expansion into adjacent healthcare products
Stable export demand
Investment View
Good option for long-term investors focused on consistent compounding.
In 2029, valuation re-rating may occur with sustained earnings visibility.
Growth Drivers
Strong order book execution
Continued government and NGO partnerships
Improved return ratios
Investment View
Favors investors seeking long-term capital appreciation.
By 2030, Cupid Ltd could emerge as a stronger global healthcare niche player.
Growth Drivers
Rising global population health initiatives
Expansion into new geographies
Strong balance sheet and cash generation
Investment View
Attractive for long-term wealth creation with relatively lower risk.
Cupid Ltd represents a niche healthcare opportunity with stable demand, export-led growth, and strong promoter backing. Its products are essential in nature, making the business relatively resilient to economic cycles.
Growing global focus on reproductive health
Strong export-oriented business model
Consistent profitability and cash flows
Low beta indicating stability
High promoter confidence
Dependence on government and tender-based orders
Currency fluctuation impacting export revenues
Regulatory changes in healthcare and medical devices
Limited product diversification
Monitoring quarterly performance and order inflows is advisable before making significant investment decisions.
Cupid Ltd has established itself as a reliable player in the healthcare and contraceptive segment, benefiting from long-term global health initiatives and steady export demand. Supported by strong fundamentals and a focused business model, the company offers attractive long-term growth potential.
Based on current trends and growth assumptions, Cupid Ltd share price could potentially reach ₹880 to ₹1,000 by 2030. For investors looking for a niche, stable, healthcare-focused stock with long-term potential, Cupid Ltd remains an interesting option.
1. What is the current share price of Cupid Ltd?
The share price is around the levels mentioned in the latest market data and changes with market movements.
2. What is the Cupid Ltd share price target for 2026?
The estimated range for 2026 is ₹520 to ₹580.
3. Is Cupid Ltd a good long-term investment?
It may be suitable for long-term investors seeking exposure to the healthcare and export-oriented segment.
4. What is the share price target for 2030?
The projected target range for 2030 is ₹880 to ₹1,000.
5. What factors influence Cupid Ltd share price the most?
Export demand, government tenders, profitability, regulatory environment, and overall market sentiment.
Disclaimer: This article is for educational purposes only and does not constitute investment advice. Please consult a financial advisor before making any investment decisions.
Register & Login